Physician profile
Chock Tsering
NPI 1386655132
$247.14
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $12.04 · 2021: $15.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $51.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.17 | 2019-2021 | |
| Shionogi INC | $28.08 | 2019 | |
| Boston Scientific Corporation | $25.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.19 | 2019 | |
| Lilly USA, LLC | $19.61 | 2019 | |
| Zyla Life Sciences, INC. | $18.20 | 2019 | |
| Allergan, INC. | $12.04 | 2020 | |
| Promius Pharma LLC | $11.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chock Tsering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.